Potassium acetate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Potassium acetate
Accession Number
DB14498  (DBSALT001427)
Type
Small Molecule
Groups
Approved, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousHospira, Inc.2005-07-07Not applicableUs
Potassium AcetateLiquid392 mgIntravenousSandoz Canada Incorporated1988-12-312016-10-24Canada
Potassium AcetateInjection, solution, concentrate196.3 mg/1mLIntravenousHospira, Inc.2013-12-23Not applicableUs
Potassium AcetateInjection, solution, concentrate392 mg/1mLIntravenousAmerican Regent1990-09-302014-07-01Us
Potassium AcetateInjection, solution196 mg/1mLIntravenousAmerican Regent1990-09-302012-11-29Us
Potassium Acetate Inj 2meq/mlSolutionIntravenousAbbott1984-12-312008-06-06Canada
Potassium Acetate Inj 392mg/ml USPLiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada
Potassium Acetate InjectionSolutionIntravenousFresenius Kabi1984-12-31Not applicableCanada
Potassium Acetate Injection USPLiquidIntravenousOmega Laboratories Ltd2016-07-18Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousExela Pharma Sciences, Llc.2016-01-07Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AminosynPotassium acetate (128 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + L-Alanine (448 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Valine (280 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phosphoric acid (40 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Tyrosine (31 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MPotassium acetate (128 mg) + Arginine (343 mg) + Glycine (448 mg) + Histidine (105 mg) + Isoleucine (252 mg) + L-Alanine (448 mg) + L-Leucine (329 mg) + L-Lysine acetate (252 mg) + L-Phenylalanine (154 mg) + L-Threonine (182 mg) + L-Tryptophan (56 mg) + L-Valine (280 mg) + Magnesium acetate (21 mg) + Methionine (140 mg) + Proline (300 mg) + Serine (147 mg) + Sodium chloride (234 mg) + Tyrosine (31 mg)LiquidIntravenousAbbott1980-12-311999-08-09Canada
Hyperlyte (multi-electrolyte Concentrate)Potassium acetate (690 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.09 g) + Magnesium acetate (860 mg) + Potassium chloride (2.46 g) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
Hyperlyte CR Multi-electrolyte ConcentratePotassium acetate (1.96 g) + Calcium Chloride (370 mg) + Magnesium chloride (510 mg) + Sodium acetate (680 mg) + Sodium chloride (1.17 g)LiquidIntravenousB. Braun Medical Inc.1998-09-03Not applicableCanada
LypholytePotassium acetate (690 mg) + Calcium acetate (440 mg) + Sodium gluconate (1.1 g) + Magnesium acetate (860 mg) + Potassium chloride (2.5 g) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjPotassium acetate (34.5 mg) + Calcium acetate (22 mg) + Sodium gluconate (55 mg) + Magnesium acetate (43 mg) + Potassium chloride (125 mg) + Sodium acetate (135 mg)LiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
Normosol-M & 5% DextrosePotassium acetate (0.128 g) + Dextrose, unspecified form (5 g) + Magnesium acetate (0.021 g) + Sodium chloride (0.234 g)SolutionIntravenousIcu Medical Canada Inc1965-12-31Not applicableCanada
Normosol-M and DextrosePotassium acetate (128 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium acetate (21 mg/100mL) + Sodium chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.1975-08-13Not applicableUs
Plasma-lyte 56Potassium acetate (1.28 mg/1mL) + Magnesium acetate tetrahydrate (.23 mg/1mL) + Sodium chloride (2.34 mg/1mL)InjectionIntravenousBaxter Laboratories2006-09-192018-10-11Us
Plasma-lyte 56 5% Dextrose InjPotassium acetate (128 mg) + Dextrose, unspecified form (5 g) + Magnesium acetate (32 mg) + Sodium chloride (234 mg)LiquidIntravenousBaxter Laboratories1990-12-312014-04-17Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hyperlyte CRPotassium acetate (1.96 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Magnesium chloride hexahydrate (0.51 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL) + Sodium chloride (1.17 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
NutrilytePotassium acetate (34.5 mg/1mL) + Calcium acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08Us
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01Us
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01Us
Potassium AcetatePotassium acetate (392 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302014-07-01Us
Potassium AcetatePotassium acetate (196 mg/1mL)Injection, solutionIntravenousAmerican Regent1990-09-302012-11-29Us
Categories
UNII
M911911U02
CAS number
127-08-2
Weight
Average: 98.1423
Monoisotopic: 97.977011201
Chemical Formula
C2H3KO2
InChI Key
SCVFZCLFOSHCOH-UHFFFAOYSA-M
InChI
InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
IUPAC Name
potassium acetate
SMILES
[K+].CC([O-])=O

Pharmacology

Indication

Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Mostly urine but also skin and feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Potassium acetate.
AceclofenacAceclofenac may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C12554
ChemSpider
29104
ChEBI
32029
ChEMBL
CHEMBL1201058
Wikipedia
Potassium_acetate
ATC Codes
B05XA17 — Potassium acetate
AHFS Codes
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Heart Failure (AHF) / Decompensated Heart Failure / Heart Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
SolutionIntravenous
Injection, solution, concentrateIntravenous
InjectionIntravenous
LiquidIntravenous
Injection, solutionIntravenous196 mg/1mL
Injection, solution, concentrateIntravenous196.3 mg/1mL
Injection, solution, concentrateIntravenous3.93 g/20mL
Injection, solution, concentrateIntravenous392 mg/1mL
LiquidIntravenous392 mg
SolutionIntravenous
LiquidIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility342.0 mg/mLALOGPS
logP-0.27ALOGPS
logP-0.22ChemAxon
logS0.54ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
Acetate salts
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Acetate salt / Organic alkali metal salt / Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic potassium salt / Organic salt / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:32029)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965]

Drug created on July 11, 2018 10:28 / Updated on November 20, 2019 12:33